Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD)


The study is designed to identify the best outcome measures in assessing their suitability and the adaptability across a variety of countries and languages for future international clinical
trials for patients with CDD.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Inclusion criteria:

Patients ages newborn to 17 years old with documented diagnosis of CDKL5 deficiency

Exclusion criteria:

Any condition that, in the opinion of the investigator, would put the patient at
undue risk or make it unsafe for the patient to participate


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Dr. Julia Jacobs-LeVan at 4039552480 or Julia.Jacobs-LeVan@albertahealthservices.ca

Principal investigator:

Julia Jacobs-Levan

Clinical trial: